文献速递肝病

验证Baveno VII标准及其他无创诊断算法在丁型肝炎相关临床显著门静脉高压中的应用

Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
PubMed 文献 · J Hepatol · 2024-03-11

在51例HDV相关代偿期进展性慢性肝病患者中回顾性验证Baveno VII标准及VITRO、SSM等无创算法对CSPH的诊断效能,Baveno VII排除CSPH敏感度100%、纳入特异度84.2%,复合风险模型AUROC达0.885-0.912,验证队列92例证实预后价值。

要点

  • Baveno VII标准排除CSPH敏感度100%,纳入CSPH特异度84.2%。
  • Baveno VII-VITRO或Baveno VII-SSM算法显著缩小灰区(41.1%)并保持诊断准确性。
  • 仅CSPH或符合Baveno VII纳入标准者2年内发生肝功能失代偿。

核心结论

  • standalone及复合无创检测/诊断算法有助于HDV-cACLD患者的CSPH诊断,无创检测可用于识别和优先安排CSPH患者接受慢性丁型肝炎新型抗病毒治疗。

研究设计与样本

  • 回顾性纳入2013至2023年在维也纳医科大学或汉诺威医学院接受配对HVPG和无创检测评估的HDV-cACLD患者(LSM≥10 kPa或组织学METAVIR F3/F4纤维化),共51例。
  • 评估LSM、VITRO和SSM,按已发表模型(ANTICIPATE、3P/5P)计算个体CSPH风险,并评估Baveno VII标准及 refined算法(Baveno VII-VITRO、Baveno VII-SSM)的诊断性能。
  • 在主队列及一个独立的92例多中心验证队列中研究无创检测的预后价值。

主要发现

  • CSPH患病率62.7%,静脉曲张42.2%。
  • CSPH患者LSM为25.8 [17.2-31.0] kPa vs 非CSPH患者14.0 [10.5-19.8] kPa(p<0.001)。
  • CSPH患者VITRO(n=31)为3.5 [2.7-4.5] %/[G/L] vs 非CSPH患者1.3 [0.6-2.0] %/[G/L](p<0.001)。
  • CSPH患者SSM(n=20)为53.8 [41.7-75.5] kPa vs 非CSPH患者24.0 [17.0-33.9] kPa(p<0.001)。
  • 复合CSPH风险模型AUROC:ANTICIPATE 0.885,3P 0.903,5P 0.912。

关键数值与推荐

  • Baveno VII标准排除CSPH敏感度100%,纳入CSPH特异度84.2%。
  • Baveno VII灰区比例为41.1%,Baveno VII-VITRO或Baveno VII-SSM算法显著缩小灰区并保持诊断准确性。
  • 2年内肝功能失代偿仅发生于CSPH患者或符合Baveno VII纳入标准者。
  • 无创检测的预后价值在92例验证队列中得到证实。

临床怎么用

  • 无创检测应应用于临床常规并每年更新,以识别HDV-cACLD短期临床事件风险患者;无创检测也可指导新型抗病毒治疗优先排序。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-invasive tests (NITs) for clinically significant portal hypertension (CSPH) require validation in patients with hepatitis D virus (HDV)-related compensated advanced chronic liver disease (cACLD). Therefore, we aimed to validate existing NIT algorithms for CSPH in this context. METHODS: Patients with HDV-cACLD (LSM ≥10 kPa or histological METAVIR F3/F4 fibrosis) who underwent paired HVPG and NIT assessment at Medical University of Vienna or Hannover Medical School between 2013 and 2023 were retrospectively included. Liver stiffness measurement (LSM), von Willebrand factor to platelet count ratio (VITRO), and spleen stiffness measurement (SSM) were assessed. Individual CSPH risk was calculated according to previously published models (ANTICIPATE, 3P/5P). The diagnostic performance of Baveno VII criteria and refined algorithms (Baveno VII-VITRO, Baveno VII-SSM) was evaluated. The prognostic utility of NITs was investigated in the main cohort and an independent, multicenter, validation cohort. RESULTS: Fifty-one patients (HVPG ≥10 mmHg/CSPH prevalence: 62.7%, varices: 42.2%) were included. Patients with CSPH had significantly higher LSM (25.8 [17.2-31.0] vs. 14.0 [10.5-19.8] kPa; p <0.001), VITRO (n = 31, 3.5 [2.7-4.5] vs. 1.3 [0.6-2.0] %/[G/L]; p <0.001), and SSM (n = 20, 53.8 [41.7-75.5] vs. 24.0 [17.0-33.9] kPa; p <0.001). Composite CSPH risk models yielded excellent AUROCs (ANTICIPATE: 0.885, 3P: 0.903, 5P: 0.912). Baveno VII criteria ruled out CSPH with 100% sensitivity and ruled in CSPH with 84.2% specificity. The Baveno VII 'grey zone' (41.1%) was significantly reduced by Baveno VII-VITRO or Baveno VII-SSM algorithms, which maintained diagnostic accuracy. Hepatic decompensation within 2 years only occurred in patients who had CSPH or met Baveno VII rule-in criteria. The prognostic value of NITs was confirmed in the validation cohort comprising 92 patients. CONCLUSIONS: Standalone and composite NIT/diagnostic algorithms are useful for CSPH diagnosis in patients with HDV-cACLD. Thus, NITs may be applied to identify and prioritize patients with CSPH for novel antiviral treatments against chronic hepatitis D. IMPACT AND IMPLICATIONS: Non-invasive tests (NITs) for clinically significant portal hypertension (CSPH) have been developed to identify patients with compensated advanced chronic liver disease (cACLD) at risk of decompensation, but conflicting data has been published regarding the accuracy of liver stiffness measurement (LSM) for the staging of fibrosis in patients infected with hepatitis D virus (HDV). In our study, including 51 patients with HDV-cACLD, LSM- and lab-based NITs yielded high AUROCs for CSPH. Moreover, only patients with CSPH or high non-invasively assessed CSPH risk were at risk of decompensation within 2 years, with the prognostic value of NITs confirmed in a validation cohort. Thus, NITs should be applied and updated in yearly intervals in clinical routine to identify patients with HDV-cACLD at short-term risk of clinical events; NITs may also guide prioritization for novel antiviral treatment options.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Jachs M, Sandmann L, Hartl L, et al. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta. J Hepatol. 2024. PMID: 38479612. doi:10.1016/j.jhep.2024.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。